MedTrace Logo

SHP-141C in Plaque Type Psoriasis

NCT01646567 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2014-07-11

No results posted yet for this study

Summary

The purpose of this study is to assess the safety, tolerability and clinical activity of the SHP-141C topical cream formulations in patients with plaque type psoriasis.

Conditions

  • Plaque Type Psoriasis

Interventions

DRUG

SHP-141C

Topical Cream

DRUG

Placebo to SHP-141C

Placebo Topical Cream

DRUG

Betamethasone Valerate

Topical cream, 0.02%

DRUG

Calcipotriol

Topical cream, 0.005%

Sponsors & Collaborators

  • TetraLogic Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Peter Foley · The Alfred

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-09-30
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01646567 on ClinicalTrials.gov